PACE/State of FL - Register now – Sept. 10, 2025

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

Conflict is a natural part of human interaction, and the workplace is not immune from that experience.  Through this microlearning, we'll explore how proper conflict[...]

PACE/State of FL - What problem-solving thinking is, as well as an overview of what DMAIC, A3, and PDSA problem-solving approaches are to support your quality and continuous improvement journey.

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.

Mayo Clinic Laboratories now offers the first preeclampsia-specific test (Mayo ID: PERA) that can be used to stratify patients into low or high-risk categories, indicating whether a patient is at risk for developing preeclampsia with severe features. With this information, clinicians can make more informed decisions about hospitalization, monitoring, more frequent checkups, and even early delivery.

This week's research roundup feature: Incapacitated regulatory T cells (Tregs) contribute to immune-mediated diseases. Inflammatory Tregs are evident during human inflammatory bowel disease (IBD); however, mechanisms driving the development of these cells and their function are not well understood. Therefore, we investigated the role of cellular metabolism in Tregs relevant to gut homeostasis.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, talks with Erin Hoffman, division director of hospital sales and services at Mayo Clinic Laboratories. They discuss the value of the hospital laboratory, the challenges and opportunities facing community labs today, and how to have impactful conversations with hospital leadership.

This week's research roundup feature: Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA), was administered in recurrent GBM patients either at the resection cavity (Group A), or, intratumorally on day 1, followed by a second dose administered in the resection cavity after tumor resection on day 5 (Group B). 

Due to a major weather impact at the FedEx hub in Memphis, Tennessee, the Mayo Clinic Laboratories’ Global Logistics team is working to minimize any client impacts. Please visit our website for updates. For any immediate needs, please contact Customer Service at 800-533-1710 and ask to be forwarded to the Global Logistics specialist. 

In a competitive outpatient testing market, choosing a laboratory is discretionary. With the goal of becoming the laboratory of choice for discretionary outpatient testing, it no longer matters if it is called “inreach” or “outreach.” While these terms may be decent descriptors for a process, they do not begin to describe the true value of this critical community laboratory activity. The value of a laboratory outreach program spans all areas of relevance for a health system. Through supporting clinical integration and community health initiatives, the laboratory is a critical element, enabled and supported by a successful outreach activity.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., and Rondell Graham, M.B.B.S., delve into the critical decisions involved in contemplating a role on the staff at the institution where you receive your training.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to talk about the sexually-transmitted disease syphilis.

This week's research roundup feature: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies.

Globally, five million deaths are associated with bacterial antimicrobial resistance each year, but the complexity of the issue is there is no single solution because we need to use antibiotics. It’s about finding a different way to live with it.